Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression-Reference-Cited by-同舟云学术

Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression

Published:2014-07 Issue: Volume:107 Page:42-49
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Beliakova-Bethell Nadejda,Jain Sonia,Woelk Christopher H.,Witt Mallory D.,Sun Xiaoying,Lada Steven M.,Spina Celsa A.,Goicoechea Miguel,Rought Steffney E.,Haubrich Richard,Dubé Michael P.

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference28 articles.

1. The effect of cell subset isolation method on gene expression in leukocytes;Beliakova-Bethell;Cytometry A,2014

2. Maraviroc versus efavirenz, both in combination with zidovudine–lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection;Cooper;J. Infect. Dis.,2010

3. CCR5 antagonism in HIV infection: ways, effects, and side effects;Corbeau;AIDS,2009

4. Immune recovery and T cell subset analysis during effective treatment with maraviroc;Cossarini;J. Antimicrob. Chemother.,2012

5. Maraviroc intensification of stable antiviral therapy in HIV-1–infected patients with poor immune restoration: MARIMUNO-ANRS 145 study;Cuzin;JAIDS,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Probing the Interface of HIV and Inflammaging;Current HIV/AIDS Reports;2021-03-11

2. Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective – a Commentary;Expert Review of Neurotherapeutics;2019-05-24

3. A novel dual-luciferase assay for anti-HIV drug screening based on the CCR5/CXCR4 promoters;Journal of Virological Methods;2018-06

4. Prognosis of HIV Patients Receiving Antiretroviral Therapy According to CD4 Counts: A Long-term Follow-up study in Yunnan, China;Scientific Reports;2017-08-29

5. The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1;Scientific Reports;2017-05-24